Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Currently receiving aripiprazole at time of screening

• Men and women ages 18 to 70

Exclusion Criteria:

• All patients previously discontinued from an aripiprazole study for any reason

• Active alcohol or substance abuse

• Patients who represent a significant risk of committing suicide

• Patients with clinically significant abnormal laboratory test results, vital signs or ECG findings